• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Atrion Corporation

    8/21/24 9:20:04 AM ET
    $ATRI
    Medical/Dental Instruments
    Health Care
    Get the next $ATRI alert in real time by email
    S-8 POS 1 tm2421866d3_s8pos.htm S-8 POS

     

    As filed with the Securities and Exchange Commission on August 21, 2024

     

    Registration No. 033-40639

    Registration No. 033-61309

    Registration No. 333-142917

    Registration No. 333-144085

    Registration No. 333-144086

    Registration No. 333-172767

    Registration No. 333-256352

     

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION NO. 033-40639

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION NO. 033-61309

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION NO. 333-142917

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION NO. 333-144085

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION NO. 333-144086

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION NO. 333-172767

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION NO. 333-256352

     

    UNDER THE SECURITIES ACT OF 1933

     

     

    ATRION CORPORATION

    (Exact Name of Registrant as Specified in Its Charter)

     

     

    Delaware   63-0821819
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)
     
    One Allentown Parkway
    Allen, Texas
      75002
    (Address of Principal Executive Offices)   (Zip Code)

     

    AlaTenn Resources, Inc. 1990 Stock Option Plan
    AlaTenn Resources, Inc. 1994 Key Employee Stock Incentive Plan

    Atrion Corporation 2006 Equity Incentive Plan

    Atrion Corporation Non-Employee Director Stock Purchase Plan

    Atrion Corporation Deferred Compensation Plan for Non-Employee Directors

    Amended and Restated Atrion Corporation 2006 Equity Incentive Plan

    Atrion Corporation 2021 Equity Incentive Plan

    (Full title of the plans)

     

    David A. Battat

    President and Chief Executive Officer

    Atrion Corporation

    One Allentown Parkway

    Allen, Texas 75002

    (Name and address of agent for service)

     

    (972) 390-9800

    (Telephone number, including area code, of agent for service)

     

    With a copy to:

    B.G. Minisman, Jr.

    Baker, Donelson, Bearman, Caldwell & Berkowitz, PC

    1901 Sixth Avenue North

    Suite 2600

    Birmingham, AL 35203

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

     

    Large accelerated filer x Accelerated filer ¨
           
    Non-accelerated filer ¨ Smaller reporting company ¨
           
    Emerging growth company ¨    

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    These Post-Effective Amendments (these “Post-Effective Amendments”) by Atrion Corporation, a Delaware corporation (the “Registrant”), relate to the following Registration Statements on Form S-8 (each, a “Registration Statement,” and collectively, the “Registration Statements”):

     

    ·Registration Statement No. 03340639, filed with the Securities and Exchange Commission (the “SEC”) by AlaTenn Resources, Inc. (“AlaTenn”), an Alabama corporation, on May 17, 1991, pertaining to the registration of 110,000 shares of the common stock of AlaTenn, par value $0.10 per share, reserved for issuance under the AlaTenn Resources, Inc. 1990 Stock Option Plan;
    ·Registration Statement No. 033-61309, filed with the SEC by AlaTenn, on July 26, 1995, pertaining to the registration of 105,000 shares of the common stock of AlaTenn, par value $0.10 per share, reserved for issuance under the AlaTenn Resources, Inc. 1994 Key Employee Stock Incentive Plan;
    ·Registration Statement No. 333-142917, filed with the SEC on May 14, 2007, pertaining to the registration of 92,500 shares of the common stock of the Registrant, par value $0.10 per share (the “Common Stock”), reserved for issuance under the Atrion Corporation 2006 Equity Incentive Plan;
    ·Registration Statement No. 333-144085, filed with the SEC on June 27, 2007, pertaining to the registration of 2,500 shares of Common Stock reserved for issuance under the Atrion Corporation Non-Employee Director Stock Purchase Plan;
    ·Registration Statement No. 333-144086, filed with the SEC on June 27, 2007, pertaining to the registration of 2,500 shares of Common Stock reserved for issuance under the Atrion Corporation Deferred Compensation Plan for Non-Employee Directors;
    ·Registration Statement No. 333-172767, filed with the SEC on March 11, 2011, pertaining to the registration of 100,000 shares of Common Stock reserved for issuance under the Amended and Restated Atrion Corporation 2006 Equity Incentive Plan; and
    ·Registration Statement No. 333-256352, filed with the SEC on May 21, 2021, pertaining to the registration of 100,000 shares of Common Stock reserved for issuance under the Atrion Corporation 2021 Equity Incentive Plan.

     

    On August 21, 2024, pursuant to the terms of an Agreement and Plan of Merger, dated as of May 28, 2024 (as it may be amended, modified or supplemented from time to time, the “Merger Agreement”), by and among Nordson Corporation, an Ohio corporation (“Nordson”), Alpha Medical Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Nordson (“Merger Sub”), and the Registrant, Merger Sub merged with and into the Registrant, with the Registrant surviving the merger as a wholly owned subsidiary of Nordson (the “Merger”).

     

    As a result of the Merger and the other transactions contemplated by the Merger Agreement, the Registrant has terminated any and all offerings and sales of its securities pursuant to the Registration Statements. In accordance with an undertaking made by the Registrant in the Registration Statements to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statements that remain unsold at the termination of the offerings, by filing these Post-Effective Amendments, the Registrant hereby removes from registration all securities registered but unsold under such Registration Statements, if any, as of the date hereof, and the Registration Statements are hereby amended, as appropriate, to reflect the deregistration of such securities and the Registrant hereby terminates the effectiveness of each Registration Statement.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Westlake, State of Texas on August 21, 2024.

     

      ATRION CORPORATION
         
      By: /s/ Jennifer McDonough
        Jennifer McDonough
        Secretary

      

    Pursuant to the Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments.

     

     

     

    Get the next $ATRI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ATRI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ATRI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Athey Preston G bought $95,904 worth of shares (300 units at $319.68), increasing direct ownership by 28% to 1,368 units (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      12/1/23 2:53:55 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Battat David A bought $90,000 worth of shares (300 units at $300.00), increasing direct ownership by 0.77% to 39,400 units (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      11/16/23 2:49:33 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Stupp John P Jr returned $69,149,960 worth of shares to the company (150,326 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 5:00:44 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Director Spaulding Ronald Nicholas returned $1,231,880 worth of shares to the company (2,678 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 4:30:30 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Director Athey Preston G returned $629,280 worth of shares to the company (1,368 units at $460.00), closing all direct ownership in the company (SEC Form 4)

      4 - ATRION CORP (0000701288) (Issuer)

      8/21/24 4:19:38 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Atrion Corporation

      15-12G - ATRION CORP (0000701288) (Filer)

      9/3/24 9:11:57 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Atrion Corporation

      S-8 POS - ATRION CORP (0000701288) (Filer)

      8/21/24 9:24:19 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • SEC Form S-8 POS filed by Atrion Corporation

      S-8 POS - ATRION CORP (0000701288) (Filer)

      8/21/24 9:23:12 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atrion Reports Second Quarter 2024 Results

      ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2024. Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 20

      8/8/24 6:00:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Atrion Corporation Enters Into Merger Agreement with Nordson Corporation

      ALLEN, Texas, May 28, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI), a developer and manufacturer of products primarily for medical applications, today announced that it has entered into an agreement and plan of merger with Nordson Corporation pursuant to which Nordson will acquire Atrion for $460 per share in cash, representing a total equity value of approximately $815 million. The transaction enterprise value reflects a multiple of 20.2 times Atrion's 2023 EBITDA, and the $460 per share price represents a 15% premium to Atrion's 90-day average daily volume-weighted average stock price. The proposed transaction was unanimously approved by the Boards of Directors of Atrion

      5/28/24 7:24:38 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies

      Expands Nordson MEDICAL's total addressable market Highly complementary with Nordson's customer base and core competencies Broadens Nordson's exposure to higher-growth and stable medical end markets Nordson to host investor call at 8:30 a.m. ET today Nordson Corporation (NASDAQ:NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (NASDAQ:ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Th

      5/28/24 7:00:00 AM ET
      $ATRI
      $NDSN
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Industrials

    $ATRI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Atrion Corporation

      SC 13G/A - ATRION CORP (0000701288) (Subject)

      9/9/24 4:05:03 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Atrion Corporation

      SC 13D/A - ATRION CORP (0000701288) (Subject)

      8/22/24 6:05:08 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Atrion Corporation

      SC 13D/A - ATRION CORP (0000701288) (Subject)

      8/22/24 6:04:56 AM ET
      $ATRI
      Medical/Dental Instruments
      Health Care

    $ATRI
    Financials

    Live finance-specific insights

    See more
    • Atrion Reports Second Quarter 2024 Results

      ALLEN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced its results for the second quarter ended June 30, 2024. Revenues for the second quarter of 2024 totaled $48.8 million compared to $43.8 million for the same period in 2023. For the just ended quarter, operating income was $0.5 million, down $6.8 million from the comparable 2023 period, and net income was $0.4 million, down $6.2 million from the same period in 2023. Operating income was significantly impacted by the accrual of $5.0 million in acquisition-related expenses discussed below. Second quarter 2024 diluted earnings per share were $0.23 compared to $3.73 for the second quarter of 20

      8/8/24 6:00:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care
    • Nordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies

      Expands Nordson MEDICAL's total addressable market Highly complementary with Nordson's customer base and core competencies Broadens Nordson's exposure to higher-growth and stable medical end markets Nordson to host investor call at 8:30 a.m. ET today Nordson Corporation (NASDAQ:NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (NASDAQ:ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion's 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. Th

      5/28/24 7:00:00 AM ET
      $ATRI
      $NDSN
      Medical/Dental Instruments
      Health Care
      Industrial Machinery/Components
      Industrials
    • Atrion Corporation Declares Quarterly Cash Dividend

      ALLEN, Texas, May 21, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ:ATRI) today announced that its Board of Directors declared a quarterly dividend of $2.20 per share on its outstanding shares of Common Stock. This dividend will be payable on June 28, 2024 to stockholders of record at the close of business on June 14, 2024. Atrion Corporation develops and manufactures products primarily for medical applications. The Company's website is www.atrioncorp.com. Contact: Cindy FergusonVice President and Chief Financial Officer(972) 390-9800         

      5/21/24 4:30:00 PM ET
      $ATRI
      Medical/Dental Instruments
      Health Care